Similar articles

• Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration.

  Ladas ID, Kotsolis AI, Papakostas TD, Rouvas AA, Karagiannis DA, Vergados I. Ladas ID, et al. Retina. 2007 Sep;27(7):891-6. doi: 10.1097/IAE.0b013e3180ca9ad9. Retina. 2007. PMID: 17891013
• Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration.

  Chen E, Kaiser RS, Vander JF. Chen E, et al. Retina. 2007 Apr-May;27(4):445-50. doi: 10.1097/01.iae.0000249574.89437.40. Retina. 2007. PMID: 17420696
• Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration.

  Ach T, Hoeh AE, Ruppenstein M, Kretz FT, Dithmar S. Ach T, et al. Retina. 2010 Oct;30(9):1420-5. doi: 10.1097/IAE.0b013e3181d87e97. Retina. 2010. PMID: 20543764
• Avastin and new treatments for AMD: where are we?

  Freeman WR, Falkenstein I. Freeman WR, et al. Retina. 2006 Oct;26(8):853-8. doi: 10.1097/01.iae.0000244722.35073.7c. Retina. 2006. PMID: 17031283 Review. No abstract available.
• Bevacizumab: a new way of doing business?

  Canning C, Lotery A. Canning C, et al. Eye (Lond). 2006 Sep;20(9):985-7. doi: 10.1038/sj.eye.6702501. Epub 2006 Jul 21. Eye (Lond). 2006. PMID: 16858443 Review.